CA-12-5 ELISA kit
| Name |
CA-12-5 ELISA kit |
|---|---|
| Full name |
Human CA-12-5 ELISA Test Kit |
| Category Name | Cancer ELISA kits |
| Test | 96 |
| Method | ELISA method: Enzyme Linked Immunosorbent Assay |
| Principle | Sandwich Complex |
| Detection Range | 0-400U/mL |
| Sample | 50ul serum |
| Specificity | 97% |
| Sensitivity | 5U/mL |
| Total Time | ~200 min |
| Shelf Life | 12 Months from the manufacturing date |
 |
 |
 |
CA-12-5 ELISA kit description:
The CA-125 EIA test is an ELISA assay for the quantitative measurement of CA-12-5 in human serum. CA125 elisa kit is primarily intended for use as a monitoring and screening test.
Material Provided with CA125ELISA Kit:
1. Microtiter wells coated with Monoclonal Anti-CA-12-5 antibody
2. CA-12-5 Elisa Enzyme conjugate reagent
3. CA12-5 Elisa Test reference standards
4. TMB Substrate
5. CA 12-5 EIA Kit Stop solution
6. CA 12-5 EIA Kit Wash Buffer Concentrate 50X
Materials Required, not Provided:
1. Precision pipettes
2. Distilled or deionized water
3. EIA kit Microplate Washer
4. EIA kit Microplate Reader with a 450 nm
CA125ELISA Kit Background Information:
Cancer Antigen 125 (CA-12-5) is a surface antigen associated with epithelial ovarian cancer. Elevated serum CA-12-5 levels can be found in individuals with serious endometroid, clear-cell and undifferentiated ovarian carcinoma. Serum CA-12-5 levels higher than normal can also be found in individuals with adenocarcinoma of the fallopian tube endometrium, certain non- gynecologic malignancies and some non-malignant conditions. The serum CA-12-5 concentration is greater than 35 units per ml in about 60% of women with ovarian cancer. More than 80% of patients with disseminated ovarian cancer, have serum CA-12-5 concentrations greater than 35 units per ml. The serum CA-12-5 is elevated in 1% of normal healthy women, 3% of normal healthy women with benign ovarian diseases, and 6% of patients with non-malignant conditions including but not limited to first trimester pregnancy, menstruation, endometriosis, uterine fibrosis, hepatic diseases and inflammation of peritoneum, pericardium or pleura.
CA125ELISA Test Principle:
The CA-12-5 Quantitative Test Kit is based on a solid phase enzyme-linked immunosorbent assay. The assay system utilizes one monoclonal anti-CA-12-5 antibody for microtiter wells) immobilization and another monoclonal anti-CA 125 antibody in the antibody-enzyme horseradish peroxidase conjugate solution. The standards and patient serum are added to the CA-12-5 antibody coated microtiter wells. Then CA-12-5 antibody labeled with conjugate is added. If human CA-12-5 is present in the specimen, it will combine with the antibody on the well and the enzyme conjugate resulting in the CA-12-5 molecules being sandwiched between the solid phase and enzyme-linked antibodies. For additional details please refer to the instructions for use.
Notable features of Cancer ELISA Kits:
User-friendly directions and explanation of test procedures
Simple and safe reagent preparation
Clear instructions on specimen collection
Comprehensive package of required materials
Explicit quality control and storage guidelines
Reliable and easy-to-read test results
Product inserts for all Cancer ELISA kits follow a similar method. See the CA125 ELISA Kit product insert for specific details on preparation, procedures, quality control, and test result interpretation.
Diagnostic Automation Inc. also provides other Autoimmune Disease ELISA Kits. For more information about ELISA Kits, Rapid Tests, IFA Kits, CLIA Test Kits, or Serology tests, please see our website home page, or contact our Customer Service Representatives at 818-591-3030 .